60 Degrees Pharmaceuticals’ (SXTP) Sell (E+) Rating Reiterated at Weiss Ratings

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating restated by equities research analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Separately, HC Wainwright reissued a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, January 10th.

60 Degrees Pharmaceuticals Trading Down 14.6 %

Shares of NASDAQ SXTP opened at $0.62 on Friday. The company has a fifty day moving average price of $1.16 and a 200 day moving average price of $1.07. 60 Degrees Pharmaceuticals has a 1-year low of $0.53 and a 1-year high of $7.20. The firm has a market cap of $1.43 million, a PE ratio of -0.06 and a beta of 4.24.

Insider Buying and Selling

In related news, CEO Geoffrey S. Dow purchased 35,823 shares of the stock in a transaction on Monday, December 9th. The shares were purchased at an average price of $1.27 per share, with a total value of $45,495.21. Following the transaction, the chief executive officer now directly owns 94,580 shares of the company’s stock, valued at $120,116.60. This trade represents a 60.97 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders acquired 66,372 shares of company stock worth $82,410. 10.27% of the stock is owned by insiders.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.